StockData
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. (APUS) stock

APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$1.95−0.09 (-4.41%)

Close on Nov 17, 2026Market cap $2.94MP/E –Yield –

Apimeds Pharmaceuticals US revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.90M–
Q2 FY2026Jun 30, 2026$282.73K–

More Apimeds Pharmaceuticals US figures

See a number that looks wrong?